Orasis Pharmaceuticals
Dr. Ron Neumann has more than 30 years of experience as an ophthalmologist and working in the pharmaceutical industry. He has held many leading roles in clinical development and marketing, such as serving as the head of ophthalmology at Teva Pharmaceutical Industries. Dr. Neumann currently works as an advisor in the field of ocular drug development. He is also the chairperson for ISOPT Clinical (The International Symposium on Ocular Pharmacology and Therapeutics).
Dr. Neumann holds an M.D. in ocular immunology from Massachusetts Eye and Ear Infirmary. He completed his fellowship program in inflammatory eye diseases at Harvard University.
This person is not in any offices
Orasis Pharmaceuticals
2 followers
Orasis is an emerging ophthalmic pharmaceutical company with the goal of making near vision clear again. They are committed to the Ophthalmology and Optometry segments because they know that presbyopia is ubiquitous. By virtue of their first in class formulation, Orasis is well-positioned to be first-line therapy in this emerging category by addressing a significant unmet need for patients.